Brad O'Connor Chief Executive Officer
Brad O’Connor has been Managing Director and Chief Executive Officer of Cogstate Limited since December 2005. Brad has responsibility for Cogstate’s overall strategic direction and day-to-day operations as well as development of expansion opportunities outside of the core clinical trials business.
Brad is also a director of Cogstate Inc. and Cogstate Sport Inc. Prior to taking the position of CEO at Cogstate, Brad joined Cogstate as Chief Financial Officer and Company Secretary in May 2004. Prior to that, Brad held senior positions at Spherion Group, Australian Wine Exchange and PricewaterhouseCoopers. Brad is a chartered accountant who holds a Bachelor of Business degree.
George Hunnewell Chief Operating Officer and President, Clinical Trials
George Hunnewell is an accomplished senior executive with more than 25 years of experience growing clinical research and healthcare technology businesses. He brings deep general management expertise including sales and marketing, operations, finance, and mergers and acquisitions.
As Chief Operating Officer and President of Cogstate’s Clinical Trials division, George is responsible for worldwide operations including Regulatory & Quality Assurance, Product Development, Human Resources, as well as full P&L responsibility for the Clinical Trials business.
George previously served as Corporate Vice President, Clinical Research Services for Parexel International Corporation, and he earned an AB in Mechanical Engineering from Harvard University and an MBA from MIT Sloan School of Management.
Frank Cheng President, Healthcare
Frank Cheng is a medical technology industry executive with general management experience with both established industry leaders and venture-backed companies.
As President of Cogstate’s Healthcare Business, Frank is responsible for all aspects of commercializing Cogstate technologies in the healthcare marketplace. For this role, Frank utilizes his deep experience in building and growing new businesses in key worldwide markets (United States, the European Union, Canada, China and Japan) through achieving regulatory clearance, reimbursement approval and commercialization build-up.
Frank most recently served as Senior Vice President, Worldwide Marketing & Business Development at cardiac robotic innovator Stereotaxis Inc., where he led the company’s marketing, business development, training, clinical research, operations, as well as Asia P&L. His previous experience includes general management roles at GE Healthcare and Roche Diagnostics. Frank holds a BBA in International Finance from Wuhan University in China and an MBA from Vanderbilt University.
Lammert Albers Chief Commercial Officer
Lammert Albers is a business development executive with more than 15 years experience in the Life Science and Healthcare industries, driving global commercial strategies for leading clinical research organizations from discovery through post-marketing clinical trials.
As Chief Commercial Officer at Cogstate, Lammert is responsible for driving growth and strategic relationships for Cogstate’s Clinical Trials business, leading marketing, proposals and business development functions globally.
Lammert comes to Cogstate from PRA Health Sciences, having served as Vice President of Global Business Development and Engagement Partner, where he lead cross-divisional commercial teams. Lammert also held the role of Vice President Global Business Development and Strategic Relationships at MDS Pharma Services (later Clearstone Central Laboratories), as well as commercial and scientific roles with Genaissance Pharmaceuticals, Anachem Ltd and AstraZeneca.
Paul Maruff Chief Scientific Officer
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioral and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods to guide decision making in drug development and in clinical medicine.
He has worked extensively on method to identify subtle neurocognitive impairment, and to assess the efficacy of pharmacological treatment, in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended this approach to identify cognitive dysfunction, and monitor treatment efficacy in psychiatric diseases such as schizophrenia, obsessive-compulsive disorder and depression in adults, and attention deficit disorder, developmental dyspraxia and substance abuse in children.
Paul remains an active researcher. He is appointed Professor at the Florey Institute for Neuroscience and Mental Health. He is currently clinical co-chair of the Australian Imaging Biomakers and Lifestyle (AIBL) study. Paul has published over 250 research articles in international peer-reviewed scientific journals, and has co-authored 10 book chapters.
Kate Jopling Operations Director, Clinical Trials
Kate Jopling is Operations Director for Cogstate Clinical Trials. Ms. Jopling has over 10 years of experience in clinical research and pharmaceutical clinical trials. Ms. Jopling is responsible for leadership, management, oversight, and alignment of the operational functional areas within Clinical Trials, including Project Management, Data Management, Biostatistics, Scales and Rater Training, Systems Logistics, and Operational Clinical Science.
Ms. Jopling joined Cogstate in 2009 and has held positions with increasing management responsibility as Senior Clinical Project Manager, Senior Clinical Data Manager, and most recently as Operations Manager. Prior to Cogstate, Ms. Jopling spent five years at a Clinical Trial Data Management Provider where she managed external vendor data acquisition.
Her clinical trials experience includes Phases I-IV studies across numerous indications, including oncology, cardiovascular, and CNS. She is passionate about operational excellence, and strives to optimize processes while building cohesive teams, ensuring quality and timely delivery to Cogstate customers.
Roger O'Sullivan General Counsel, Corporate Secretary and Chief Privacy Officer
Mr. O’Sullivan has extensive experience as legal counsel for the healthcare and life sciences industries, bringing broad, frontline experience establishing strategic alliances and structuring and negotiating complex commercial/corporate transactions.
As Cogstate’s General Counsel, Corporate Secretary (Cogstate Inc.) and Chief Privacy Officer, Mr. O’Sullivan serves as key legal advisor on all major business transactions. He also oversees regulatory compliance and the development and protection of the company’s intellectual property portfolio.
Prior to joining Cogstate, Mr. O’Sullivan was founder and managing member of a New York life sciences boutique where he counseled small to mid-size biopharmaceutical companies regarding formation and strategic development.
Claire Newstead-Sinclair Finance Manager and Company Secretary
Ms. Newstead-Sinclair was appointed to the position of Company Secretary in 2010, prior to which she worked as a Finance Manager for OAMPS Insurance Brokers, part of the Wesfarmers Group. Claire studied accounting at Monash University and was admitted as a member of the Institute of Chartered Accountants in April 2004.
Cindy Durkin Operations Director, Healthcare
Ms. Durkin has over 20 years experience in Healthcare, from direct patient care to managing the measurement of cognition for portfolios of large global clinical trials. Since 2006, Cindy has held positions of increasing responsibility at Cogstate. She currently leads the strategic planning, execution and product development for Cogstate’s Healthcare business unit; dedicated to providing clinicians with tools for accurate and easy measurement of cognitive function in clinical practice.
Prior to joining Cogstate, Cindy served as a staff nurse at the Hospital of Saint Raphael (CT) and Beth Israel Deaconess Medical Center (MA). Clinical experience includes Cardiothoracic ICU, Medical/Cardiac ICU and Medical/Renal units. In addition, Ms. Durkin worked as a Clinical Research Associate for a CRO, as well as Clinical Trial Manager for OXiGENE, Inc.
Tanya Chenhall Director, Research and Development
Tanya Chenhall is Director of Research and Development at Cogstate with over 10 years experience in product development and trial management for measuring cognition in clinical research. Ms Chenhall joined Cogstate in 2005 and since then has held positions of increasing responsibility. She currently leads a highly talented cross functional team of product development, project management and scientific experts in new product development, task development, academic research, investigator-initiated clinical trials and cognitive pre-screening solutions for recruitment into clinical trials.